Venables boards Ark as CEO
This article was originally published in Scrip
Viral product focused Ark Therapeutics has appointed David Venables CEO with effect from 1 August 2012, replacing outgoing CEO Martyn Williams. Mr Venables joined Ark's board of directors in April this year (scripintelligence.com, 10 April 2012) from Intercell where he served as COO. Mr Williams joined the company in 1998 and has been CEO since mid-2010. He will leave Ark on 31 July.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.